Inhibition of CYP1B1 by TMS reduced blood pressure, decreased vascular reactivity, cardiovascular hypertrophy, endothelial and renal dysfunction, and cardiac and renal fibrosis. This evidence concerns the gene CYP1B1 and Abnormal renal physiology.